



What Makes CRESTOR® (rosuvastatin calcium) Different?

CRESTOR effectively lowers LDL-C (bad) cholesterol and raises HDL-C (good) cholesterol

- Across the dose range, CRESTOR has been shown to provide a 45-63% reduction in LDL-C and up to a 14% increase in HDL-C, versus a 7% LDL-C reduction and 3% HDL-C increase with placebo.
- CRESTOR is contraindicated in patients with active liver disease, and in women who are pregnant, nursing or could become pregnant.

CRESTOR is also the only branded statin indicated to slow the progression of atherosclerosis in adult patients with elevated cholesterol at any stage of the disease

- CRESTOR is a once-daily prescription statin medication indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hyperlipidemia, mixed dyslipidemia and isolated hypertriglyceridemia, available in a 5-, 10-, 20-, and 40-mg dose. In November 2007, the FDA approved CRESTOR to slow the progression of atherosclerosis in patients with elevated cholesterol as part of a treatment strategy to lower total-C and LDL-C, based largely on the results of a pivotal study called METEOR (Masuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin).
- METEOR measured the effects of CRESTOR on plaque-build up in the arteries using b-mode ultrasonography to measure carotid intima-media thickness (CIMT). Results demonstrated a slowing of progression of atherosclerosis in people taking CRESTOR 40 mg with early signs of the disease, elevated LDL cholesterol, and low cardiovascular risk.
 - CRESTOR 40 mg should only be used for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.



CRESTOR has been shown to significantly reduce LDL-C and raise HDL-C in trials comparing its efficacy with that of atorvastatin, simvastatin, and pravastatin

- The STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study was a six-week, randomized, open-label study comparing the efficacy of specific doses and the dose range of CRESTOR with specific doses and the dose ranges of atorvastatin, pravastatin and simvastatin in patients with primary hypercholesterolemia.
- In STELLAR, 2,431 patients with hypercholesterolemia (LDL-C \geq 160 mg/dL and $<$ 250 mg/dL; triglycerides $<$ 400 mg/dL) were randomized to one of 15 open-label treatment arms for six weeks. Results showed:

STELLAR RESULTS		
Treatment	LDL-C Reduction	HDL-C Increase
CRESTOR 10-40 mg	46-55%	7.6-9.6%
atorvastatin 10-80 mg	37-51%	5.7-2.0%
simvastatin 10-80 mg	28-46%	5.3-6.8%
pravastatin 10-40 mg	20-30%	3.2-5.5%

CRESTOR is not significantly metabolized by cytochrome P450

CRESTOR is a hydrophilic (water soluble) statin, rather than lipophilic (fat soluble)

CRESTOR has received regulatory approval in over 97 countries and has been launched in 76 markets

- Worldwide, over 13 million patients have been prescribed CRESTOR and more than 140 million prescriptions have been written through August 2008.

About CRESTOR

CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR has not been determined to prevent heart disease, heart attacks or strokes. For patients with hyperlipidemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. The 40 mg dose of CRESTOR is reserved for only those patients who have not achieved their LDL-C goal utilizing the 20 mg dose of CRESTOR once-daily. When initiating statin therapy or switching from another statin therapy, the appropriate CRESTOR starting dose should first be utilized, and only then titrated according to the patient's individualized goal of therapy.

For more information about CRESTOR, including full Prescribing Information, visit www.crestor.com.

Important Safety Information

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of the product and in patients with active liver disease or unexplained persistent elevations of hepatic transaminase, in women who are pregnant or may become pregnant, and in nursing mothers. Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with drugs in this class, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir. Combination therapy with rosuvastatin and gemfibrozil should be avoided. CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy, such as renal impairment, advanced age, and inadequately treated hypothyroidism. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. CRESTOR is generally well-tolerated. The most frequent adverse reactions thought to be related to CRESTOR were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of \$29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a \$13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit www.astrazeneca-us.com.

For further information contact:

Donna Huang
Associate Director, Brand Corporate Affairs, AstraZeneca
302-885-6396
Donna.Huang@astrazeneca.com

CRESTOR is a registered trademark of the AstraZeneca group of companies.

© 2008 AstraZeneca Pharmaceuticals, LP. All rights reserved.

###